You are here

Clinical Trials: Cord Blood

Condition:   Leukemia
Interventions:   Biological: aldesleukin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Conditions:   Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Myeloid, Acute;   Burkitt Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse
Interventions:   Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation;   Biological: GVHD prophylaxis
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
Completed
Conditions:   Stem Cell Transplantation;   Leukemia;   Lymphoma
Interventions:   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin (ATG);   Drug: G-CSF (Filgrastim);   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mesna
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting
Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
Sponsors:   Columbia University;   Duke University
Completed
Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Immunodeficiencies;   Anemia
Interventions:   Drug: TBI, Thiotepa, Cyclophosphamide, ATG;   Drug: Busulfan, Melphalan, Rabbit ATG;   Drug: Busulfan, Fludarabine, Alemtuzumab;   Drug: Busulfan, Fludarabine, Rabbit ATG;   Drug: Fludarabine, Cyclophosphamide, ATG;   Drug: Busulfan, Cyclosphosphamide, Rabbit ATG,
Sponsor:   Columbia University
Terminated
Conditions:   Acute Biphenotypic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Myelodysplastic Syndrome;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   RAEB-2;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified June 2017
Condition:   Severe Osteopetrosis
Interventions:   Procedure: umbilical cord blood transplantation;   Drug: Campath-1H;   Radiation: Total Lymphoid Irradiation;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Procedure: marrow graft transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Unknown status
Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia;   Hodgkins Lymphoma
Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting - verified September 2017
Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Indolent Non-Hodgkin Lymphoma;   Malignant Lymphoma, Large Cell Type;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Non-Hodgkin Lymphoma
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Suspended
Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2017

Pages